Elutia (ELUT) Competitors $1.03 -0.02 (-1.90%) Closing price 04:00 PM EasternExtended Trading$1.01 -0.02 (-1.46%) As of 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ELUT vs. SXTC, SGMT, PRQR, ACRS, VOR, IPHA, TLSA, TNYA, TRDA, and EPRXShould you be buying Elutia stock or one of its competitors? The main competitors of Elutia include China SXT Pharmaceuticals (SXTC), Sagimet Biosciences (SGMT), ProQR Therapeutics (PRQR), Aclaris Therapeutics (ACRS), Vor Biopharma (VOR), Innate Pharma (IPHA), Tiziana Life Sciences (TLSA), Tenaya Therapeutics (TNYA), Entrada Therapeutics (TRDA), and Eupraxia Pharmaceuticals (EPRX). These companies are all part of the "pharmaceutical products" industry. Elutia vs. Its Competitors China SXT Pharmaceuticals Sagimet Biosciences ProQR Therapeutics Aclaris Therapeutics Vor Biopharma Innate Pharma Tiziana Life Sciences Tenaya Therapeutics Entrada Therapeutics Eupraxia Pharmaceuticals China SXT Pharmaceuticals (NASDAQ:SXTC) and Elutia (NASDAQ:ELUT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, media sentiment, risk, dividends and earnings. Do analysts prefer SXTC or ELUT? Elutia has a consensus target price of $7.00, suggesting a potential upside of 579.61%. Given Elutia's stronger consensus rating and higher probable upside, analysts clearly believe Elutia is more favorable than China SXT Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score China SXT Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Elutia 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility & risk, SXTC or ELUT? China SXT Pharmaceuticals has a beta of 1.35, meaning that its share price is 35% more volatile than the S&P 500. Comparatively, Elutia has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500. Is SXTC or ELUT more profitable? China SXT Pharmaceuticals has a net margin of 0.00% compared to Elutia's net margin of -90.01%. Company Net Margins Return on Equity Return on Assets China SXT PharmaceuticalsN/A N/A N/A Elutia -90.01%N/A -54.08% Which has higher valuation and earnings, SXTC or ELUT? China SXT Pharmaceuticals has higher earnings, but lower revenue than Elutia. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioChina SXT Pharmaceuticals$1.74M105.97-$3.30MN/AN/AElutia$23.68M1.84-$53.95M-$1.06-0.97 Do institutionals and insiders believe in SXTC or ELUT? 5.0% of China SXT Pharmaceuticals shares are held by institutional investors. Comparatively, 74.0% of Elutia shares are held by institutional investors. 4.0% of China SXT Pharmaceuticals shares are held by insiders. Comparatively, 27.6% of Elutia shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media refer more to SXTC or ELUT? In the previous week, China SXT Pharmaceuticals and China SXT Pharmaceuticals both had 1 articles in the media. China SXT Pharmaceuticals' average media sentiment score of 1.89 equaled Elutia'saverage media sentiment score. Company Overall Sentiment China SXT Pharmaceuticals Very Positive Elutia Very Positive SummaryElutia beats China SXT Pharmaceuticals on 6 of the 11 factors compared between the two stocks. Get Elutia News Delivered to You Automatically Sign up to receive the latest news and ratings for ELUT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ELUT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELUT vs. The Competition Export to ExcelMetricElutiaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$43.67M$3.07B$5.65B$10.29BDividend YieldN/A2.36%5.68%4.62%P/E Ratio-0.9720.7675.8426.11Price / Sales1.84403.84517.46171.25Price / CashN/A45.9137.5661.52Price / Book-0.799.6212.876.30Net Income-$53.95M-$52.73M$3.29B$271.03M7 Day Performance-4.63%0.64%-0.26%-0.15%1 Month Performance-56.90%6.31%3.84%6.41%1 Year Performance-72.46%18.97%68.35%28.81% Elutia Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELUTElutia3.3829 of 5 stars$1.03-1.9%$7.00+579.6%-71.5%$43.67M$23.68M-0.97180Positive NewsHigh Trading VolumeSXTCChina SXT Pharmaceuticals1.2986 of 5 stars$1.83-1.6%N/A-69.6%$210.13M$1.74M0.0090Positive NewsGap UpSGMTSagimet Biosciences3.4325 of 5 stars$6.37+0.1%$25.67+303.2%+154.5%$207.13MN/A-3.488PRQRProQR Therapeutics2.4723 of 5 stars$1.96-1.5%$8.00+308.0%+25.0%$205.69M$16.49M-4.25180Positive NewsACRSAclaris Therapeutics2.6171 of 5 stars$1.86+0.8%$8.71+369.8%+61.2%$200.95M$18.72M-1.35100Positive NewsVORVor Biopharma2.6371 of 5 stars$1.58-1.6%$6.07+285.2%+125.3%$199.53MN/A-0.95140Analyst UpgradeGap DownIPHAInnate Pharma2.7472 of 5 stars$2.14+2.9%$11.00+414.0%-17.3%$198.66M$12.62M0.00220Analyst RevisionGap UpTLSATiziana Life Sciences0.5865 of 5 stars$1.70-0.1%N/A+114.1%$198.06MN/A0.008News CoverageTNYATenaya Therapeutics2.8068 of 5 stars$1.20-0.4%$6.25+423.0%-20.8%$194.76MN/A-1.24110TRDAEntrada Therapeutics2.6148 of 5 stars$5.10+0.7%$25.67+403.8%-66.6%$193.81M$210.78M-2.86110News CoveragePositive NewsEPRXEupraxia Pharmaceuticals2.0677 of 5 stars$5.28-0.8%$11.00+108.3%+104.8%$189.80MN/A-6.2129News CoveragePositive News Related Companies and Tools Related Companies SXTC Competitors SGMT Competitors PRQR Competitors ACRS Competitors VOR Competitors IPHA Competitors TLSA Competitors TNYA Competitors TRDA Competitors EPRX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ELUT) was last updated on 9/25/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Elutia Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Elutia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ELUT Stock Alerts